Pfizer Faces Lawsuit Over Depo-Provera Risks, First Trial Set for December 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Businesswire
- Litigation Progress: Over 2,100 women are pursuing litigation against Pfizer, alleging inadequate warnings regarding the risks of Depo-Provera, with the first trial scheduled for December 2026, highlighting the urgency and potential financial implications of these legal actions.
- FDA Warning Update: The FDA's recent approval of a label change for Depo-Provera, adding a warning about the risk of intracranial meningioma, underscores regulatory pressure on Pfizer regarding drug safety, which could impact its market reputation.
- Surge in Lawsuits: There has been a fivefold increase in lawsuits since May 2023, indicating that more women are reporting serious health issues linked to Depo-Provera, potentially exposing Pfizer to significant liability for damages.
- Legal Accountability Investigation: A law firm is investigating potential breaches of fiduciary duties by Pfizer's Board of Directors related to the marketing and sale of Depo-Provera, which could affect corporate governance and shareholder trust.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 25.280
Low
24.00
Averages
29.08
High
34.00
Current: 25.280
Low
24.00
Averages
29.08
High
34.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
